Emyria Ltd (ASX:EMD) has been granted a trading halt by the ASX ahead of the release of an announcement regarding regulatory registration of the company’s Openly remote health monitoring application.
The company’s securities will remain halted until the start of normal trading on Thursday, May 13, 2021, or until an announcement is released to the market.
Shares last traded at 22 cents after reaching 26 cents last week.
Psychedelic-assisted therapy program
Earlier this month, Emyria and partner Mind Medicine Australia launched the EMDMA-001 psychedelic-assisted therapy program targeting sufferers of treatment-resistant post-traumatic stress disorder (PTSD).
As a first step, and pending ethics approval, Emyria will sponsor a major, independently monitored, clinical trial targeting treatment-resistant PTSD with evidence-based MDMA-assisted therapy.
Key priority
A key priority of this first program is to help evaluate the long-term safety, efficacy and cost benefits of MDMA-assisted psychotherapy.
Such evidence is needed, along with fit-for-purpose clinical infrastructure and trained therapists, in order to deliver psychedelic-assisted care in a safe, standardised and scalable way.